1. Home
  2. BCAB vs CISO Comparison

BCAB vs CISO Comparison

Compare BCAB & CISO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • CISO
  • Stock Information
  • Founded
  • BCAB 2007
  • CISO 2015
  • Country
  • BCAB United States
  • CISO United States
  • Employees
  • BCAB N/A
  • CISO N/A
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • CISO Computer Software: Prepackaged Software
  • Sector
  • BCAB Health Care
  • CISO Technology
  • Exchange
  • BCAB Nasdaq
  • CISO Nasdaq
  • Market Cap
  • BCAB 31.5M
  • CISO 31.4M
  • IPO Year
  • BCAB 2020
  • CISO N/A
  • Fundamental
  • Price
  • BCAB $0.72
  • CISO $1.35
  • Analyst Decision
  • BCAB Hold
  • CISO
  • Analyst Count
  • BCAB 3
  • CISO 0
  • Target Price
  • BCAB $1.00
  • CISO N/A
  • AVG Volume (30 Days)
  • BCAB 1.1M
  • CISO 663.2K
  • Earning Date
  • BCAB 11-06-2025
  • CISO 08-14-2025
  • Dividend Yield
  • BCAB N/A
  • CISO N/A
  • EPS Growth
  • BCAB N/A
  • CISO N/A
  • EPS
  • BCAB N/A
  • CISO N/A
  • Revenue
  • BCAB $11,000,000.00
  • CISO $28,792,765.00
  • Revenue This Year
  • BCAB N/A
  • CISO N/A
  • Revenue Next Year
  • BCAB N/A
  • CISO N/A
  • P/E Ratio
  • BCAB N/A
  • CISO N/A
  • Revenue Growth
  • BCAB N/A
  • CISO N/A
  • 52 Week Low
  • BCAB $0.24
  • CISO $0.30
  • 52 Week High
  • BCAB $2.53
  • CISO $3.84
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 56.79
  • CISO 76.30
  • Support Level
  • BCAB N/A
  • CISO $1.21
  • Resistance Level
  • BCAB $0.84
  • CISO $1.32
  • Average True Range (ATR)
  • BCAB 0.07
  • CISO 0.10
  • MACD
  • BCAB -0.00
  • CISO 0.04
  • Stochastic Oscillator
  • BCAB 85.96
  • CISO 80.20

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About CISO CISO Global Inc.

CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.

Share on Social Networks: